Vittorio Gebbia

Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

Charles E. Geyer, Judy E. Garber, Richard D. Gelber et al. · Annals of Oncology · 2022 · 447 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study

PierFranco Conte, Antonio Frassoldati, Giancarlo Bisagni et al. · Annals of Oncology · 2018 · 155 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Patients With Cancer and COVID-19: A WhatsApp Messenger-Based Survey of Patients’ Queries, Needs, Fears, and Actions Taken

Vittorio Gebbia, Dario Piazza, Maria Rosaria Valerio et al. · JCO Global Oncology · 2020 · 70 citations · Full text

Social Sciences, Oncology, Health Communication +14

9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: Results of the phase III multicentric Italian study Short-HER.

PierFranco Conte, Giancarlo Bisagni, Antonio Frassoldati et al. · Journal of Clinical Oncology · 2017 · 36 citations · Full text

Medicine, Oncology, Pharmacology +17

Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial

Maria Vittoria Dieci, Giancarlo Bisagni, Alba A. Brandes et al. · BMC Medicine · 2019 · 25 citations · Full text

Medicine, Oncology, Breast Oncology +16